Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
Atul A DeodharDésirée van der HeijdeJoachim SieperFilip Van den BoschWalter P MaksymowychTae Hwan KimKishimoto MitsumasaAndrew OstorBernard CombeYunxia SuiAlvina D ChuIn-Ho SongPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib.